GlassScriptPhysician profile
Nathan Dudley Maples
NPI 1689803603
$2,193.11
in general payments reported to CMS, 2019-2025
38 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $314 · 2021: $253 · 2022: $313 · 2023: $214 · 2024: $217 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $609.25 | 2019-2025 | Da Vinci Surgical System |
| Allergan, INC. | $164.70 | 2019-2022 | |
| Kerecis Limited | $111.10 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Tetraphase Pharmaceuticals, INC. | $97.09 | 2019-2020 | |
| Ethicon US, LLC | $92.30 | 2019-2024 | Harmonic |
| Trevena, INC. | $84.48 | 2021-2022 | |
| Abbvie INC. | $80.15 | 2019-2024 | |
| Tela Bio, INC. | $65.99 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Smith+Nephew, INC. | $64.41 | 2020-2025 | Renasys Touch, Pico |
| Integra Lifesciences Corporation | $60.30 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Conmed Corporation | $60.14 | 2024-2025 | Airseal |
| Polynovo North America LLC | $59.29 | 2023 | |
| Access Pro Medical, LLC | $50.02 | 2023 | Matriderm |
| Organogenesis INC. | $48.86 | 2024 | |
| Covidien LP | $46.82 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.71 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $40.58 | 2022-2023 | Exparel |
| Hologic INC | $40.36 | 2022 | |
| Myriad Genetic Laboratories, INC. | $31.71 | 2021-2025 | Myrisk |
| Acera Surgical, INC. | $29.28 | 2019-2021 | |
| Davol INC. | $26.53 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $24.26 | 2024 | |
| Paratek Pharmaceuticals, INC. | $24.25 | 2025 | Nuzyra |
| Innovation Technologies INC | $21.95 | 2025 | Irrisept |
| Medela LLC | $19.71 | 2021 | |
| Ambu INC. | $18.76 | 2023 | |
| Focal Therapeutics, INC. | $17.87 | 2019 | |
| Teleflex LLC | $17.69 | 2020 | |
| Genentech USA, INC. | $16.97 | 2020 | |
| Baxter Healthcare | $16.92 | 2021 | |
| Heron Therapeutics, INC. | $16.38 | 2022 | |
| Kci USA, INC. | $16.26 | 2023 | V.A.C. Veraflo Cleanse Choice |
| Solventum Corporation | $16.26 | 2024 | Prevena |
| Takeda Pharmaceuticals U.S.A., INC. | $14.36 | 2021 | |
| Reprise Biomedical, INC. | $14.12 | 2025 | Miro3d |
| Inari Medical, INC. | $13.88 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Coopersurgical, INC. | $12.28 | 2020 | |
| Bolder Surgical LLC | $7.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Maples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.